# Switching Between GLP-1 Drugs

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-11-10

Canonical page: https://glpwatchdog.org/research/switching-between-glp1-drugs

> No label contains a dose equivalence between semaglutide and tirzepatide, because no regulator has been asked to approve one. Every conversion chart online is somebody's arithmetic.

## Key points

- No published dose equivalence exists between these drugs, on any label.
- They act at different receptors: tirzepatide at two, semaglutide at one.
- A new drug is a new titration: the semaglutide and tirzepatide labels start low and escalate no faster than every four weeks.
- The hard part is the gap, when the old drug is fading while the new one climbs.

People switch between these drugs constantly, whether for supply, cost or side effects, or because one stopped working. The obvious question is what dose you land on, and the answer is that **no validated equivalence exists**. Every conversion chart circulating online is somebody’s arithmetic, not a labeled fact.

## Why there is no conversion

Dose equivalence gets established when a regulator is asked to approve one. Nobody has asked, because no manufacturer has an interest in demonstrating that its drug can be swapped for a competitor’s. So the tables do not exist. The question matters, but no one has been required to answer it.

There is also a mechanistic reason not to expect a clean conversion. Tirzepatide acts at two receptors, GIP and GLP-1; semaglutide acts at one. They are not the same drug at different strengths, and a milligram of one has no defined relationship to a milligram of the other. Our [tirzepatide timeline](https://glpwatchdog.org/research/tirzepatide-results-timeline) covers why even their trial results cannot be read against each other. At the brand level the labels differ too: [Ozempic and Zepbound](https://glpwatchdog.org/compare/drugs/ozempic-vs-zepbound) are approved for different jobs, Ozempic for type 2 diabetes and Zepbound for weight management.

> A conversion chart implies a relationship that no regulator has approved and no trial has established.

## What the labels actually say

What every label does say is how to start, and they all say it the same way.

- **Start at the lowest dose.** Every drug in this class has an opening dose intended to be tolerated rather than to work.
- **Escalate no faster than every four weeks** on the semaglutide and tirzepatide labels. The interval is about the gut adjusting, not about the drug accumulating.
- **Increase as tolerated.** The labels deliberately leave room for a prescriber to hold or step back.

Applied to a switch, the labels give an unwelcome but consistent default: each drug has its own ladder, and none says where to join it from another drug. Someone comfortable at a high dose of one may still start at the bottom of the other’s ladder, and the weeks that follow can feel like starting over because physiologically they are.

> **Prescribers do sometimes start higher than the label’s opening dose when switching**, on the reasoning that someone already tolerating one GLP-1 has adapted somewhat. That is a clinical judgment made with knowledge of your history, and it is the judgment a telehealth intake form cannot make. It is also not something to negotiate for because a restart is annoying. There is some evidence behind it. In SURPASS-SWITCH-2, a single-arm Lilly study, 152 adults with type 2 diabetes stable on another GLP-1 moved straight to tirzepatide 5 mg, skipping 2.5 mg.[2] A 2026 expert paper proposes approximate dose bands, while conceding that no switching guidelines exist and that prospective trials are still needed.[3] Neither changes a label.

## Reasons to switch, ranked by how good they are

1. **Side effects you cannot tolerate.** The best reason, and now supported by comparative data showing that drugs in this class differ measurably by symptom, which we cover in [the side-effect ranking](https://glpwatchdog.org/research/which-glp1-has-the-worst-side-effects). An allergic reaction is a different case: see [allergic reactions and anaphylaxis](https://glpwatchdog.org/research/glp1-allergic-reactions-and-anaphylaxis) before switching.
2. **Supply.** A real and common reason, and the one that leaves people least choice.
3. **Cost or coverage.** Legitimate, and worth confirming the new price is durable rather than promotional before restarting a ladder. Formularies move too: [CVS Caremark dropped Zepbound for Wegovy in 2025 and restored it in October 2026](https://glpwatchdog.org/research/cvs-caremark-zepbound-coverage).
4. **“It stopped working.”** The weakest reason on its own, because a plateau is expected rather than a failure, and switching restarts the climb regardless.

## What to expect in the gap

These drugs are long-acting, so stopping one does not clear it immediately. Semaglutide has a half-life of about a week, which means meaningful drug remains for several weeks after the last dose. Overlapping two of them is a prescriber’s decision and not a matter of picking a date.

Expect appetite to return before the new drug reaches a working dose. That gap, with the old drug fading and the new one still climbing, is where most of the difficulty of switching lives. Knowing it is coming is most of managing it.

## Frequently asked questions

### What dose of tirzepatide equals my semaglutide dose?

There is no validated equivalence. A 2026 expert paper proposes approximate dose bands, but no trial has confirmed them. No label contains a conversion table, because no regulator has been asked to approve one. The drugs also act at different receptors (tirzepatide at two, semaglutide at one), so there is no reason to expect a fixed relationship between their doses.

### Do I have to start at the lowest dose again?

That is the default every label's titration schedule implies, since none gives a starting point from another drug. Prescribers sometimes start higher on the reasoning that you have already adapted to the class, and one single-arm study moved people with diabetes straight to tirzepatide 5 mg, but that is a clinical judgment made with your history in front of them.

### How long should I wait between drugs?

That is a prescriber's decision, not a date to pick. These drugs are long-acting. Semaglutide's half-life is about a week, so meaningful drug remains for several weeks after the last dose.

### Will I regain weight while switching?

Appetite generally returns before the new drug reaches a working dose, and that gap is where most of the difficulty of switching lives. Knowing it is coming is most of managing it.

### Is 'it stopped working' a good reason to switch?

It is the weakest of the common reasons. Weight loss slowing is expected rather than a failure, and switching restarts the dose ladder regardless, so the first months on the new drug may look worse than the plateau that prompted the change.

## References

1. GLP Watchdog. FDA-approved labeling for semaglutide and tirzepatide products — titration schedules and the absence of any labeled cross-drug dose equivalence. DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/
2. Eli Lilly and Company A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2), NCT05706506. ClinicalTrials.gov. 2024. https://clinicaltrials.gov/study/NCT05706506
3. Schwartzberg E, Berman E, Shani S, et al. Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses. Expert Opinion on Pharmacotherapy. 2026. PMID: 42952336. DOI: 10.1080/14656566.2026.2756017. https://pubmed.ncbi.nlm.nih.gov/42952336/

---

Cite as: GLP Watchdog, Ruth Calder, "Switching Between GLP-1 Drugs", published 2026-08-19, updated 2026-11-10. https://glpwatchdog.org/research/switching-between-glp1-drugs

Canonical HTML page: https://glpwatchdog.org/research/switching-between-glp1-drugs

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
